New Issue: Credit Suisse prices $10 million two-year review notes on stocks, fund

By Sarah Lizee

Olympia, Wash., Jan. 21 – Credit Suisse AG, London Branch priced $10 million of 0% review notes due Jan. 17, 2025 linked to the least performing of the iShares MSCI Emerging Markets ETF and AbbVie Inc. and Target Corp. shares, according to a 424B2 filing with the Securities and Exchange Commission.

The notes will be called at par plus a call premium of 14.65% per year if each underlying asset closes at or above its initial level on the first review date or at or above its 50% barrier level on the final review date.

If the notes are not called, the payout at maturity will be par plus the return of the worst performing stock or fund.

J.P. Morgan Securities LLC and JPMorgan Chase Bank, NA are the placement agents.

Issuer:	Credit Suisse AG, London Branch
Issue:	Review notes
Underlying assets:	iShares MSCI Emerging Markets ETF and AbbVie Inc. and Target Corp. shares
Amount:	$10 million
Maturity:	Jan. 17, 2025
Price:	Par
Payout at maturity:	1% loss for each 1% decline of worse performing stock or fund
Call:	At par plus 14.65% per year if each asset closes at or above initial level on annual review dates or at or above 50% barrier level on final review date
Initial levels:	$88.20 for AbbVie, $125.26 for Target, $46.04 for ETF
Barrier levels:	$44.10 for AbbVie, $62.63 for Target, $23.02 for ETF, 50% of initial levels
Strike date:	Jan. 14
Pricing date:	Jan. 15
Settlement date:	Jan. 21
Agents:	J.P. Morgan Securities LLC and JPMorgan Chase Bank, NA
Fees:	0.35%
Cusip:	22551NJU1

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.